ARRY - Array BioPharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.55
+0.05 (+0.11%)
At close: 4:00PM EDT

46.11 -0.44 (-0.95%)
After hours: 7:29PM EDT

Stock chart is not supported by your current browser
Previous Close46.50
Open46.60
Bid46.07 x 800
Ask46.58 x 3000
Day's Range46.42 - 46.68
52 Week Range12.56 - 47.05
Volume12,822,551
Avg. Volume4,519,535
Market Cap10.385B
Beta (3Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.40
Trade prices are not sourced from all markets
  • Motley Fool9 hours ago

    Is Pfizer Overpaying for Array Biopharma?

    The $11.5 billion acquisition price values the target at a 62% premium.

  • Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years
    Investor's Business Dailyyesterday

    Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years

    Dow Jones component Pfizer could become a leader in colon cancer treatment with its looming $11.4 billion acquisition of biotech company Array BioPharma, an analyst said Wednesday.

  • Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
    Zacksyesterday

    Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

    A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

  • Benzingayesterday

    A Beloved Biotech ETF Could Lure Traders Again

    The Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) is one of the premier avenues for juicing short-term biotechnology returns and the triple-leveraged fund is doing just that with a gain of 21.21% over the past week. As Monday's news of Pfizer Inc. (NYSE: PFE) acquiring Array BioPharma (NASDAQ: ARRY) indicates, there remains robust appetite among larger, blue-chip biotechnology and pharmaceuticals companies for their more nimble peers, particularly the companies with immunotherapy and oncology exposure. There have been some other catalysts fueling LABU's recent run, including some political help.

  • Big Drugmakers That May Tread the M&A Path After Pfizer
    Zacksyesterday

    Big Drugmakers That May Tread the M&A Path After Pfizer

    There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
    PR Newswire2 days ago

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

    NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (PFE).

  • Motley Fool2 days ago

    Papa John’s Auditor Swap Is Not a Good Look

    The pizza purveyor once again proves itself incapable of not making matters worse, this time with a very poorly timed change.

  • Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
    Zacks2 days ago

    Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

    Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

  • Cancer Therapy Stocks Soar After Pfizer Deal
    Investopedia2 days ago

    Cancer Therapy Stocks Soar After Pfizer Deal

    Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.

  • Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
    Zacks2 days ago

    Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

    Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.

  • Company News For Jun 18, 2019
    Zacks2 days ago

    Company News For Jun 18, 2019

    Companies In The News Are: DISH,TMUS,S,ARRY,PFE,BID,BA

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Array Biopharma Inc.

    Array Biopharma Inc NASDAQ NMS:ARRYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ARRY with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ARRY are favorable, with net inflows of $2.42 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
    MarketWatch2 days ago

    Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

    Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.

  • GlobeNewswire3 days ago

    Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Array BioPharma Inc. (NASDAQ: ARRY) on Behalf of Array Shareholders and Encourages Array Investors to Contact the Firm

    NEW YORK, June 17, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Array BioPharma, Inc. (NASDAQ: ARRY) on behalf of.

  • What Happened in the Stock Market Today
    Motley Fool3 days ago

    What Happened in the Stock Market Today

    Acquisitions made headlines, with Pfizer buying Array BioPharma and a private investor picking up Sotheby's.

  • Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
    Motley Fool3 days ago

    Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

    The big drugmaker is spending more than $11 billion for the cancer-drug specialist.

  • How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers
    Investor's Business Daily3 days ago

    How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers

    Dow Jones component Pfizer is buying biotech company Array BioPharma in an $11.4 billion deal that reaps the rewards of two approved cancer treatments. Array stock soared to a record high.

  • Dow Jones Today: Almost a Case of the Mondays
    InvestorPlace3 days ago

    Dow Jones Today: Almost a Case of the Mondays

    On the surface, the gains notched by the major U.S. equity benchmarks to start the week were not all that impressive. The Nasdaq Composite led the way, climbing 0.62%, while the S&P 500 and the Dow Jones Industrial Average each finished higher by 0.09%.Source: Shutterstock However, there were pockets of excitement throughout the market today, helped by the return of Merger Monday. Dow component Pfizer (NYSE:PFE), one of the largest U.S. pharmaceuticals companies, is looking to bolster its oncology offerings by acquiring cancer treatment maker Array BioPharma (NASDAQ:ARRY) for $48 a share in cash, putting an enterprise value of about $11.4 billion on the company.Pfizer has one of the larger cash stockpiles among the major U.S. pharmaceuticals companies and checks many of the quality boxes. However, there are some concerns the Array deal could be credit negative.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCredit ratings aside, traditional pharmaceuticals companies need growth, and buying makers of cancer drugs is one avenue for delivering that growth. Other ChatterApple (NASDAQ:AAPL) stock, always a widely watched bellwether as it is the largest technology name in the Dow, traded modestly higher Monday although some analysts expressed concern about the impact of the China trade war on the stock and how the company is positioned for a fuller 5G rollout next year. * 7 Top-Rated Biotech Stocks to Invest In Today "JPMorgan analyst Samik Chatterjee cut his forecast for iPhone shipments for the next few quarters by 4%, and trimmed his price target on the stock to $233 from $235," reports Barron's. "But he maintains an Overweight rating on the shares, asserting that the trade tensions are likely to be resolved."Sticking with Dow technology names for a moment, Intel (NASDAQ:INTC), one of the largest semiconductor makers, is trying to snap out of a funk that has the stock down nearly 15% in the current quarter. Much of that tumble is attributable to semiconductor companies' sensitivity to the trade war with China, but for long-term investors, there are reasons to be optimistic about Intel."We concede that 2019 will be strenuous for Intel because of macro weakness, U.S.-China tensions, and share loss, but overall revenue growth should eventually stabilize," said Morningstar in a recent note. "As Intel gets back on track in 2020 with its 10-nm Ice Lake server parts, we think its data center group, or DCG, will enjoy average top-line growth of 10% through 2023."Boeing (NYSE:BA), a frequent guest in this space and the Dow's largest component, was the blue-chip index's best performer Monday, adding 2.2%. The company said it has no plans to rename the controversial 737 max passenger jet.At the Paris Airshow Monday, the aerospace giant boosted its 20-year demand forecast for passenger jets to $6.8 trillion, up from a previous estimate of $6.3 trillion."The world's largest planemaker said at the Paris Airshow it expected 44,040 new airplane deliveries over the next two decades, up from the roughly 43,000 it forecast a year ago," according to Reuters. Bottom Line on the Dow Jones TodayOverall, a little under half of the Dow's 30 components closed higher today, hardly a great percentage and risks remain for investors to consider. Looking out to later in June, FedEx Corp. (NYSE:FDX) reports fiscal fourth-quarter results on June 25, and while the freight shipping company is not a member of the Dow Jones Industrial Average, it is a member of the Dow Jones Transportation Index, and a bellwether stock at that.Mired in a slump that has seen the shares slide almost 5% this month, FedEx stock lost another half percent Monday after JPMorgan lowered its price target on the stock to $184 from $202. Tennessee-based FedEx has been a guidance offender multiple times over the past year and it appears that bad news is poised to continue.Again, FedEx is not a Dow stock, nor is it the largest company in the U.S. Not even close, but transportation names are historically accurate gauges of economic sentiment the market's tolerance for risk so there could be some tests coming for stocks before June ends.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post Dow Jones Today: Almost a Case of the Mondays appeared first on InvestorPlace.

  • Pfizer acquires Array in 2nd major Boulder bioscience merger this month
    American City Business Journals3 days ago

    Pfizer acquires Array in 2nd major Boulder bioscience merger this month

    Array BioPharma Inc. (Nasdaq: ARRY) has been acquired by Pfizer Inc. (NYSE: PFE). The Boulder-based biopharmaceutical firm focused on the commercialization of small molecule medicines to treat cancer and other diseases is being acquired for about $11.4 billion, or $48 per share. Upon approval by each company's board and the close of the deal, Array’s employees will join Pfizer and will continue to be located in Boulder.

  • 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA
    InvestorPlace3 days ago

    5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA

    Indices tiptoed higher on Monday, but investors are waiting to hear what the Federal Reserve has to say later this week before making any drastic moves. That's not stopping some companies from pouncing though, as M&A continues to be a theme over the last few weeks. Let's let a deal kick off our top stock trades for Tuesday. Top Stock Trades for Tomorrow 1: Pfizer Click to EnlargePfizer (NYSE:PFE) stock is in the news following its $11.4 billion acquisition of Array Biopharma (NASDAQ:ARRY) for $48 per share. The deal sent the latter up by more than 50%, while the former is trying to breakout over resistance as well.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top-Rated Biotech Stocks to Invest In Today PFE stock has been a better sell than buy up near $43 to $43.50, and a solid buy down near $40. That said, with shares holding up on news of this deal -- actually eking out a gain on Monday -- and trading north of all three of its major moving averages, it looks okay on the long side.If it can clear $43.50 though, it WILL be setting up as a breakout. Over that and $45 is in sight, with even higher prices possible should PFE push through. Top Stock Trades for Tomorrow 2: Gilead Sciences Click to EnlargeThe PFE deal has biotech trading higher on the day and Gilead Sciences (NASDAQ:GILD) is no exception. Shares are up more than 1% on the day, as GILD stock pushes through its 200-day moving average.The 200-day happens to overlap with $76 range resistance, so perhaps this area knocks the stock down once more. However, if GILD can push through, a run up to $70 is possible. If it is resistance, a decline down to the 50-day is expected, with a possible decline down to uptrend support being possible. Top Stock Trades for Tomorrow 3: Tesla Click to EnlargeShares of Tesla (NASDAQ:TSLA) are moving really well on Monday, up over 5% on the day and up over $225. It puts the 50-day moving average in play currently at $231.45, as well as channel resistance near $235 to $240.Should Tesla rally this far, it would be a logical place to book profits for traders. Above it and former range support between $250 to $260 comes into play. In May that area acted as resistance for TSLA.On a pullback -- either from current levels or after tagging resistance -- see that channel support (blue line) holds. Ideally though, the 20-day will act as support for Tesla. Top Stock Trades for Tomorrow 4: Facebook Click to EnlargeThe big blue box on the Facebook (NASDAQ:FB) chart above represents the gap that was created from the company's disappointing quarterly results 11 months ago.Shares have pushed into this gap twice, in August 2018 and Q2 2019. Neither time has the stock been able to "fill" the gap all the way back up.With FB stock now jumping higher though, is the third time a charm? Maybe. Shares have climbed aggressive off the $160 lows and 200-day moving average, up almost $30 per share in just a few weeks. FB previously topped out near $196 and needs to push through this mark, as well as prior uptrend support (blue line) to fill the gap even more.The 61.8% is at $182.34, while the 50-day is at $182.18. So long as it holds $182, FB looks okay on the long side. Below and it can get a little choppier. Top Stock Trades for Tomorrow 5: Netflix Click to EnlargeNetflix (NASDAQ:NFLX) stock has been highly responsive to this $340 to $342 level. Buyers gobble it up each time NFLX dips in this area of range support. * The 7 Best Tech Stocks to Buy for the Second Half of 2019 That makes it a simple setup, and simple is what we like when it comes to trading. Below the 200-day and traders can cut their losses when dip-buying into this area. Now up a quick 10 points, let's see how NFLX handles the 50-day moving average. Above it could send Netflix to range resistance up near $380.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA appeared first on InvestorPlace.

  • Barrons.com3 days ago

    Pfizer Is Buying Array BioPharma, Seeking to Broaden Lineup of Cancer Drugs

    The pharmaceutical company Pfizer said it would buy Array BioPharma, a maker of cancer drugs, for $48 a share in cash.

  • ETF Trends3 days ago

    Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal

    Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...

  • Barrons.com3 days ago

    Pfizer Is the Latest Drug Company to Put Its Credit Rating at Risk With M&A

    S&P Ratings has put Pfizer on watch for a downgrade after the pharma giant said it plans to acquire a cancer-drug maker.

  • We might be on a verge of a gigantic market bubble
    Yahoo Finance3 days ago

    We might be on a verge of a gigantic market bubble

    There has been some rather interesting activity in the markets the past month or so.